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INT ROD UCT ION
Th17 cells are characterized by the production of the cyto-
kines IL-17A, -17F, -21, and -22 and play a key role in defense 
against extracellular pathogens, as well as in the induction of 
autoimmune diseases (Bettelli et al., 2007; Korn et al., 2009). 
Recently, it has become clear that Th17 cells can exist in 
different states that have different functions and are marked 
by coexpression of IL-17 with other cytokines (Lee et al., 
2012). In humans, coexpression of IL-17 and IFN-γ in Th17 
cells is critical for defense against Candida albicans infection, 
whereas cells that produce IL-17 together with IL-10 are ef-
fective against Staphylococcus aureus. Expression of IFN-γ in 
Th17 cells is enhanced by IL-1β signaling, which suppresses 
IL-10 production in Th17 cells (Zielinski et al., 2012). Patho-
genicity of Th17 cells to induce autoimmune diseases in mice 
is also associated with increased levels of IFN-γ, as well as 
high expression of T-bet, IL-23R, and IL-22 (Ghoreschi et al., 
2011; Peters et al., 2011; Lee et al., 2012). In vitro activation of 
T cells in the presence of IL-1β + IL-6 results in generation 
of a highly pathogenic Th17 subset (Yang et al., 2008; Gho-
reschi et al., 2011). Similarly, the presence of TGF-β3 rather 
than TGF-β1, as well as exposure to IL-1 and -23, induces a 
pathogenic phenotype in Th17 cells (Peters et al., 2011; Lee 
et al., 2012). In contrast, Th17 cells that coexpress IL-10 with 
-17 are nonpathogenic in murine models of autoimmunity 
(Lee et al., 2012), and exposure of these Th17 cells to IL-23 
renders them pathogenic by decreasing IL-10 expression 
(McGeachy et al., 2007). Thus, IL-1β and -23 play a critical 
role in inducing and maintaining a pathogenic phenotype and 
effector functions in Th17 cells.
Co-stimulatory signals such as PD-1, CTLA-4, and 
ICOS have been shown to be involved in the differentiation 
of Th17 cells. The PD-1–PD-L1 pathway is recognized to 
be important for the maintenance of peripheral tolerance, 
and it inhibits the differentiation of Th17 cells (Francisco 
et al., 2010). The addition of PD-L1–neutralizing antibody 
completely abolishes IL-27–mediated inhibition of Th17 cell 
differentiation (Hirahara et al., 2012). CTLA-4 also controls 
the differentiation of Th17 cells. Ying et al. (2010) reported 
that CTLA-4–B7 interaction inhibits Th17 differentiation in 
vitro and in vivo and suppresses Th17-mediated autoimmu-
nity. Although ICOS is not essential for the differentiation of 
Th17 cells, ICOS plays a critical role in their maintenance, 
as ICOS-deficient mice demonstrated a defect in the ex-
pansion of Th17 cells after IL-23 stimulation (Bauquet et 
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al., 2009). Therefore, PD-1 and CTLA-4 are important for 
the regulation of Th17 differentiation, and ICOS is essential 
for the maintenance and expansion of Th17 cells. However, 
whether there are other co-stimulatory pathways that regu-
late the pathogenic/nonpathogenic phenotype of Th17 cells 
has not been addressed.
We recently performed single-cell RNA-seq profiling of 
pathogenic versus nonpathogenic Th17 cells to identify can-
didate regulators of Th17 pathogenicity (Gaublomme et al., 
2015). These data suggest the presence of two anticorrelated 
modules influencing Th17 function—a proinflammatory 
module in covariance with IL17a and a regulatory module 
correlating with expression of Il10. Among the newly identi-
fied genes that are in covariance with the regulatory module 
of Th17 pathogenicity, protein C receptor (PRO CR) stood 
out as an interesting candidate. In our studies on the tran-
scriptional network of differentiating Th17 cells, we identi-
fied Procr mRNA to be strongly induced in Th17 (Yosef et 
al., 2013); however, whether PRO CR plays a functional role 
in T cells was not investigated. Previous studies have shown 
that PRO CR, which is also known as endothelial PRO CR 
(EPCR), plays an important role in mediating intracellular 
effects of activated protein C (aPC; Esmon, 2012; Gleeson 
et al., 2012; Montes et al., 2012). aPC is used therapeutically 
to reduce mortality in patients with severe sepsis (Cao et al., 
2010; Kerschen et al., 2010; Della Valle et al., 2012). Thus far, 
PRO CR expression has been reported to be limited to a 
subset of CD8+ conventional DCs among immune cells, and 
PRO CR-expressing DCs were identified as critical targets 
of aPC therapy (Kerschen et al., 2010). Interestingly, com-
parative proteomic profiles identified protein C inhibitor to 
be present in chronic active plaque of multiple sclerosis (MS) 
patients, and recombinant aPC reduced disease severity of ex-
perimental autoimmune encephalomyelitis (EAE; Han et al., 
2008). In this setting, both the anticoagulant and the signaling 
functions of aPC contributed to the amelioration of disease 
(Han et al., 2008). However, whether aPC inhibits the enceph-
alitogenic T cell response by directly engaging PRO CR on T 
cells was not addressed.
In this study, we found that PRO CR is specifically 
expressed on the cell surface of Th17 cells where it regu-
lates their function. The transcription factors that are crit-
ical drivers of Th17 differentiation (STAT-3, IRF-4, and 
RORγt) regulate PRO CR expression. PRO CR expression 
inversely correlates with the pathogenicity of Th17 cells, and 
we found PRO CR overexpression or engagement reduced 
expression of some of the key members of the proinflam-
matory module in Th17 cells, including IL-1R and -23R, 
the two key receptors that drive the pathogenic phenotype 
of Th17 cells. Furthermore, using active immunization and 
adoptive transfer models of EAE, we showed that loss or 
reduction in the expression of PRO CR led to an increase 
in Th17 pathogenicity and enhanced EAE in vivo. In this 
study, we therefore identified PRO CR as a negative regula-
tor of Th17 pathogenicity.
RES ULTS
PRO CR is specifically expressed in Th17 cells
To identify candidate regulators of Th17 pathogenicity, we 
recently performed single-cell RNA-seq of Th17 cells dif-
ferentiated under pathogenic (IL-1β + IL-6 + IL-23) versus 
nonpathogenic (TGF-β1 + IL-6) conditions in vitro or of 
Th17 cells isolated ex vivo from the lymph nodes or central 
nervous system of mice undergoing EAE (Gaublomme et al., 
2015). We identified two distinct modules influencing Th17 
pathogenicity. The proinflammatory module is in covariance 
with Il17a, whereas the regulatory module correlates with 
expression of Il10, Il9, and others. We reasoned that surface 
molecules that are in covariance with the regulatory module 
might identify novel regulators that modulate Th17 pathoge-
nicity and therefore play a critical role in patients suffering 
from autoimmune diseases. We queried our dataset for poten-
tial candidates and identified PRO CR as an interesting can-
didate. Although we had previously reported Procr mRNA 
expression in Th17 cells (Yosef et al., 2013), its functional role 
in these cells was not evaluated. We found PRO CR to co-
vary with the regulatory module in our dataset, suggesting 
it might play a role in inhibiting Th17 pathogenicity. First, 
we wanted to validate the expression of PRO CR in Th17 
cells differentiated under nonpathogenic (TGF-β1 + IL-6) 
conditions. Transcriptional expression of Procr in Th17 cells 
was already detectable at 48 h and reached peak after 5 d of in 
vitro differentiation in nonpathogenic differentiation condi-
tions (Fig. 1 A). Procr expression was restricted to Th17 cells, 
but was not expressed on other in vitro–differentiated T cell 
subsets such as Th0 (no cytokines), Th1 (IL-12), Th2 (IL-4), 
Th9 (IL-4 + TGF-β1), Tr1 (IL-27), or induced regulatory T 
cells (TGF-β1; Fig.  1 B). Furthermore, the cell surface ex-
pression of PRO CR protein on Th17 cells, but not other T 
cell subsets, was also confirmed by flow cytometry (Fig. 1 C).
As PRO CR is selectively expressed in Th17 cells, we 
reasoned that its expression in T cells might be regulated by 
Th17-specific transcription factors. RORγt is a key tran-
scription factor that promotes development of the Th17 lin-
eage. To determine whether RORγt also controls PRO CR 
expression, we first analyzed its expression in Th17 cells 
from RORγt-deficient mice. Indeed, PRO CR expression 
in RORγt−/− Th17 cells was strongly reduced but not com-
pletely abolished compared with WT Th17 cells (Fig. 2 A), 
indicating that RORγt positively regulates PRO CR ex-
pression. We next queried the genomic chromatin immu-
noprecipitation (ChIP)-seq dataset of RORγt binding and 
identified two binding sites in the genomic locus of PRO CR 
containing the TAG GTCA/TGG GTCA RORγt-binding 
motif (Ciofani et al., 2012; Xiao et al., 2014). Using these 
genomic segments, we undertook a ChIP-PCR analysis to 
determine whether RORγt binds to the defined genomic 
elements in the Procr promoter. Indeed, ChIP-PCR data 
confirmed that RORγt can directly bind to the Procr pro-
moter (Fig. 2 D). In addition to RORγt, IRF4 and STAT-3 
are the critical transcription factors that promote the Th17 
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differentiation program; therefore, we tested whether IRF4 
and STAT3 could also regulate PRO CR expression. In-
deed, Th17 cells lacking IRF4 (CD4CreIRF4fl/fl) or STAT3 
(CD4CreSTAT3fl/fl) displayed reduced PRO CR protein ex-
pression under Th17-differentiating conditions (Fig. 2, B and 
C). By identifying the binding sites for IRF4 and STAT3 from 
genome wide ChIP-seq data (Kwon et al., 2009), we designed 
ChIP-PCR primers and again performed ChIP-PCR analy-
sis to determine whether IRF4 and STAT-3 would physically 
bind to the Procr genomic region. Like RORγt, IRF4 and 
STAT-3 significantly bound to their respective binding motifs 
that were identified in the Procr promoter (AAN NGA AA for 
IRF4 and TTC TGA GA for STAT-3; Fig. 2 D). The Il23r pro-
moter used as a positive control showed enriched binding to 
all three transcription factors (Fig. 2 D). To functionally vali-
date whether RORγt, IRF4, and STAT3 can transactivate the 
Procr promoter, we tested their ability to induce expression 
of a luciferase reporter gene under the control of the Procr 
reporter. Co-transfection of the Procr luciferase reporter with 
constructs encoding for RORγt, IRF4, or STAT3 resulted in 
enhanced luciferase activity (Fig.  2  E). The co-transfection 
of all three transcription factors resulted in additive transac-
tivation of the construct, further supporting the notion that 
they act together to promote Procr expression. Collectively, 
our data suggest that the surface receptor PRO CR is specifi-
cally expressed in Th17 cells and that its expression in T cells 
is controlled by the concerted action of the Th17 lineage- 
specific transcription factors RORγt, IRF4, and STAT3.
PRO CR regulates Th17 differentiation
As PRO CR is specifically expressed in Th17 cells, we next 
analyzed whether it also plays a role in Th17 differentiation 
by using cells that are deficient in PRO CR. Because the total 
“knock-out” mice are embryonically lethal, we used PRO CR 
low expressor (EPCRδ/δ) mice. EPCRδ/δ mice have an al-
tered 5′-untranslated region of the Procr gene, which results 
in severely reduced expression of PRO CR (Castellino et al., 
2002). The mice are viable and do not have a phenotype in 
their immune cells or T cell homeostasis (Fig. 3 A), as exem-
plified by the expression of equal numbers of CD4+, CD8+, 
and Foxp3+ regulatory T cells in generative and peripheral 
lymphoid organs. We stimulated naive CD4+ T cells from WT 
and EPCRδ/δ mice under Th17 differentiation conditions 
and analyzed their cytokine profile. Loss of PRO CR resulted 
in a slight but not significant difference in Il17a mRNA 
expression (Fig.  3 B). However, under Th17 differentiation 
conditions, cell from EPCRδ/δ mice generated significantly 
more IL-17A producing Th17 cells at the protein level as de-
termined by intracellular cytokine staining (Fig. 3 C). IFN-γ 
production by Th1 cells was not altered in EPCRδ/δ cells. To 
further extend these observations, we tested whether PRO CR 
engagement by its ligand aPC could affect expression of IL-17 
Figure 1. PRO CR is specifically induced in Th17 
cells. (A) Kinetic expression of Procr mRNA was 
measured by quantitative RT-PCR in Th17 cells dif-
ferentiated with TGF-β1 + IL-6. (B) Procr mRNA 
expression was measured by quantitative RT-PCR 
analysis in different T cell subsets after 72 h of stim-
ulation in the presence of the indicated cytokines. 
(C) PRO CR protein expression was examined by flow 
cytometry in different T cell subsets generated as 
in B. Representative plots of three to four indepen-
dent experiments are shown.
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in differentiating Th17 cells. Indeed, the frequency of IL-17+ 
CD4+ T cells was slightly but significantly reduced when WT 
Th17 cells were activated in the presence of aPC (Fig. 3, D 
and E). In contrast, aPC had no effect on IL-17 production 
in EPCRδ/δ cells (Fig. 3, D and E), confirming that aPC in-
hibits Th17 differentiation through engagement of PRO CR 
and this effect is lost in the absence of PRO CR. These results 
indicate that engagement of PRO CR by its ligand aPC leads 
to a modest inhibition of Th17 differentiation.
PRO CR controls the pathogenic signature genes of Th17 
cells and inhibits expression of IL-23R and IL-1R
As PRO CR expression covaries with the regulatory module 
in our single-cell RNA-seq analysis of Th17 cells, we specu-
lated that PRO CR might affect pathogenicity of Th17 cells. 
We previously defined a transcriptional gene signature of 23 
genes, which discriminates pathogenic from nonpathogenic 
Th17 cells (Lee et al., 2012) and used this to test our hypoth-
esis. We analyzed expression of the pathogenic Th17 signa-
Figure 2. Rorγt, IRF4, and STAT3 bind the Procr promoter and induce PRO CR expression. Naive CD4+ T cells from Rorγt KO mice (A), CD4CrexIRF4fl/fl 
mice (B), or CD4CrexSTAT3fl/fl mice (C) and control mice were polarized under Th17 conditions (TGF-β1 and IL-6) or without cytokines (Th0) as control. On day 
3, PRO CR expression was determined by flow cytometry. (D) Purified WT naive CD4+ T cells were differentiated into Th17 cells in the presence of TGF-β1 and 
IL-6. After 4 d, binding of Rorγt, IRF4, or STAT3 to the Procr and IL23r promoters was assessed by ChIP-PCR (TF, transcription factor; mean ± SD of triplicates). 
(E) Procr promoter activity was measured in HEK293T cells transfected with a luciferase vector driven by 1,040 bp of the Procr promoter (pGL4-Procr), and 
the indicated transcription factor expression constructs (mean ± SD of triplicates). Representative plots of two to three independent experiments are shown.
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ture in PRO CR+ vs. PRO CR− Th17 cells in the single-cell 
RNA-seq Th17 dataset and found a significant enrichment of 
the pathogenic signature in PRO CR− Th17 cells (Fig. 4 A). 
We then tested PRO CR expression on in vitro differenti-
ated Th17 subsets generated under different conditions. Naive 
CD4+ T cells were stimulated under either pathogenic (IL-1β 
Figure 3. Role of PRO CR in Th17 differentiation. (A) Cells from spleen, peripheral LNs, and thymus were isolated from WT and EPCRδ/δ mice, and fre-
quencies of CD8+, CD4+, memory CD62L−CD44+CD4+, naive CD62L+CD44−CD4+, and regulatory Foxp3+CD4+ T cells were determined by flow cytometry (four 
mice/group). (B–E) Naive CD4+ T cells from WT and EPCRδ/δ mice were differentiated into Th17 cells by anti-CD3/anti-CD28 stimulation in the presence of 
TGF-β1 + IL-6 (T1+6) or no cytokines (Th0) or IL-12 as control. Il17a, Ifng, and Procr mRNA levels were determined after 96 h using quantitative PCR (B), 
and IL-17A and IFN-γ protein secretion, as well as PRO CR expression levels, were examined by flow cytometry (C). (D and E) Cells were differentiated by 
anti-CD3/anti-CD28 stimulation with or without 300 nM aPC and cytokine production was analyzed 96 h later using flow cytometry (D) and ELI SA (E). (B–D) 
Bar graphs represent mean ± SD of three independent experiments; Student’s t test; *, P < 0.05; ns, not significant.
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+ IL-6 + IL-23) or nonpathogenic (TGF-β1 + IL-6) differ-
entiation conditions, and Procr mRNA expression was de-
termined by quantitative RT-PCR. Whereas Procr mRNA 
was detected in both subsets, expression was significantly 
higher in the nonpathogenic Th17 cells induced by TGF-β1 
+ IL-6 (Fig. 4 B). The qPCR data were confirmed by flow 
cytometry, where a higher frequency of PRO CR+ cells was 
detected in the nonpathogenic Th17 cells (Fig. 4 C). These 
results are in line with the data obtained from the single-cell 
RNA-seq analysis and suggest that PRO CR expression 
on Th17 cells inversely correlates with their expression of 
pathogenic signature genes.
IL-23 plays a critical role in the differentiation of patho-
genic versus nonpathogenic Th17 cells (Awasthi et al., 2009; 
Ghoreschi et al., 2011; Lee et al., 2012). Activation of naive T 
cells in the presence of TGF-β + IL-6 induces Th17 cells that 
are generally nonpathogenic in models of autoimmunity, but 
exposure of these cells to IL-23 results in the acquisition of 
a pathogenic Th17 phenotype (McGeachy et al., 2007; Peters 
et al., 2011; Lee et al., 2012). In addition, IL-23R expres-
sion on T cells is essential for Th17 stability and pathogenicity 
(Cua et al., 2003; Awasthi et al., 2009; Lee et al., 2012). Based 
on the inverse correlation between PRO CR expression and 
Th17 pathogenicity, we hypothesized that IL-23 signaling 
might affect PRO CR expression and vice versa. To test this 
hypothesis, we determined PRO CR levels on nonpathogenic 
(TGF-β1 + IL-6) and pathogenic (TGF-β1 + IL-6 + IL-23) 
Th17 cells from WT and IL-23R–deficient mice. Addition of 
IL-23 reduced the expression of PRO CR in Th17 cells from 
WT mice, when added to TGF-β1 + IL-6 differentiation 
conditions (Fig. 4 D). However, loss of IL-23R in IL-23R 
KO mice increased the expression of PRO CR and brought 
it back to the levels observed in WT T cells activated under 
nonpathogenic Th17 conditions (Fig. 4 D).
To test whether PRO CR might in turn regulate IL-
23R expression, we analyzed Il23r expression in EPCRδ/δ T 
cells differentiated in nonpathogenic versus pathogenic Th17 
conditions. Indeed, Th17 cells from EPCRδ/δ mice differen-
tiated in both pathogenic and nonpathogenic Th17 conditions 
showed an increased Il23r mRNA expression in the absence 
of PRO CR (Fig. 4 E). Furthermore, increased expression of 
IL-23R in the absence of PRO CR could be confirmed on 
the protein level (Fig. 4 F), indicating that PRO CR regulates 
IL-23R expression. In addition to IL-23R signaling, IL-1R 
plays an important role in inducing pathogenic Th17 cells 
and in promoting Th17 pathogenicity in the context of EAE 
(Sutton et al., 2006; Chung et al., 2009). We therefore sought 
to determine whether PRO CR also regulated expression of 
IL-1R. Th17 cells generated from EPCRδ/δ mice showed 
increased expression of Il1r1 mRNA under both pathogenic 
and nonpathogenic Th17 conditions (Fig.  4  G). To further 
confirm this observation, we tested the effect of loss of PRO 
CR signaling on the expression of IL1-R expression at the 
protein level by flow cytometry. WT Th17 cells differenti-
ated under nonpathogenic Th17 differentiation conditions 
(TGF-β1 + IL-6) showed very little expression of IL-1R but 
loss of PRO CR led to a profound increase in the expression 
of IL-1R, even under nonpathogenic Th17 differentiation 
conditions. Similarly under pathogenic Th17 differentiation 
conditions, T cells derived from EPCRδ/δ mice showed a 
substantial increase in the expression of IL-1R (Fig.  4  H). 
These data suggest that PRO CR signaling negatively regu-
lates expression of IL-23R and IL-1R, both of which are 
important drivers of pathogenic Th17 cells.
We next tested whether PRO CR could affect any of 
the genes that comprise the proinflammatory and regula-
tory modules in Th17 cells by comparing their expression in 
WT and EPCRδ/δ Th17 cells (Fig. 4 I). Loss of PRO CR in 
EPCRδ/δ Th17 cells led to an increase in the expression of 
approximately half of the proinflammatory signature genes 
tested when compared with WT Th17 cells. Conversely, 
expression of some nonpathogenic genes was decreased in 
EPCRδ/δ Th17 cells. The most strongly affected genes in-
cluded Il3, Cxcl3, Ccl4, Csf2, and Il9. Engagement of PRO CR 
by its ligand aPC, as well as overexpression of PRO CR 
by retroviral transduction (not depicted), resulted in a de-
crease in the expression of members of the proinflammatory 
module (Cxcl3, Il3, Ccl4, Il23r, and Il1r; Fig. 4  J). In line 
with these results, in the absence of PRO CR expression of 
Cxcl3, Il3, Ccl4, Il23r, and Il1r1 was increased in Th17 cells 
(Fig. 4 K). PRO CR therefore acts as a negative regulator of 
some of the key members of the proinflammatory module. 
Most importantly, this includes regulation of expression of 
both IL-23R and -1R, both of which play a critical role in 
promoting pathogenicity of Th17 cells.
PRO CR dampens Th17 pathogenicity in vivo
Th17 cells are the main drivers of several autoimmune dis-
eases, including EAE, the animal model of MS. Interestingly, 
comparative proteomic profiles of chronic active plaques in 
MS patients identified protein C inhibitor, which limits the 
expression of the PRO CR ligand aPC, to be present within 
these plaques (Han et al., 2008). Furthermore, in vivo ad-
ministration of recombinant aPC was able to reduce the se-
verity in EAE (Han et al., 2008). However, it is not clear 
how administration of aPC inhibited development of EAE. 
We hypothesized that these effects might be a result of the 
action of aPC on its receptor PRO CR on Th17 cells. First, 
we wanted to determine whether PRO CR was expressed 
on T cells during EAE in vivo. To this end, we induced EAE 
by immunizing mice subcutaneously with MOG35-55 peptide 
in CFA, and then analyzed PRO CR expression in T cells 
isolated from spleen, lymph node, and CNS by flow cytom-
etry at the peak of disease. Although PRO CR was not de-
tected on T cells in spleen or draining lymph nodes, it was 
highly expressed in CNS-infiltrating T cells, where Th17 cells 
were observed at the highest frequency (Fig.  5  A). To test 
whether PRO CR plays a functional role in EAE, we immu-
nized WT and EPCRδ/δ mice for EAE induction, analyzed 
the resulting T cell response, and monitored the mice for 
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the development of clinical disease. To determine the mag-
nitude of the MOG35-55-specific T cell response, we isolated 
cells from spleen and lymph nodes 10 d after immunization 
and restimulated them with MOG35-55 peptide in vitro. T 
cells derived from EPCRδ/δ mice that lack PRO CR dis-
played slightly but not significantly increased proliferative re-
sponses (Fig. 5 B). Furthermore, IL-17 and IFN-γ production 
of T cells isolated from spleen and draining lymph node of 
Figure 4. PRO CR regulates genes of the proin-
flammatory module in Th17 cells. (A) Th17 cells 
differentiated in vitro with TGF-β1 + IL-6 were an-
alyzed using single-cell RNA-seq (Gaublomme et 
al., 2015), and Procr expression in these cells was 
correlated with the pathogenic Th17 signature (Lee 
et al., 2012). P = 1.18 × 10−3 (Wilcoxon ranks test 
comparing signature scores of Procr+ vs. Procr– 
cells). (B and C) Naive CD4+ T cells from WT mice 
were differentiated into Th17 cells by anti-CD3/
anti-CD28 stimulation in the presence of TGF-β1 
+ IL-6 (T1+6), IL-1β + IL-6 + IL-23 (1+6+23), or 
no cytokines as control (Th0). PRO CR expression 
was determined by quantitative RT-PCR (B) and 
flow cytometry (C) 72 h later. Representative plots 
of three independent experiments are shown. (D) 
WT or IL-23R KO Th17 cells generated by anti-CD3/
anti-CD28 stimulation in the presence of TGF-β1 
+ IL-6 (T1+6), TGF-β1 + IL-6 + IL-23 (T1+6+23), or 
no cytokines as control were analyzed for PRO CR 
expression and IL-17 secretion by flow cytometry 
72 h later. Representative plots of three indepen-
dent experiments are shown. (E–H) Naive CD4+ T 
cells from WT and EPCR δ/δ mice were differen-
tiated into Th17 cells as in B. IL-23R (E and F) and 
IL-1R1 (G and H) expression was determined by 
quantitative RT-PCR (E and G; mean ± SD of three 
independent experiments) and flow cytometry (F 
and H) 96 h later. (I) Quantitative RT-PCR analysis 
of pathogenic and nonpathogenic signature genes 
in WT (filled bars) and EPCR δ/δ (open bars) Th17 
cells at 96 h. (J and K) Quantitative RT-PCR anal-
ysis of pathogenic and nonpathogenic signature 
genes (J) in Th17 cells differentiated with TGF-β1 + 
IL-6 with or without (Ctl) aPC and (K) in Th17 cells 
from WT or EPCRδ/δ (δ/δ) mice after 3 d of culture. 
(I–K) Bar graphs represent mean ± SEM of at least 
three independent experiments.
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EPCRδ/δ mice was significantly increased upon restimula-
tion with MOG35-55 peptide (Fig.  5  C). Most importantly, 
EPCRδ/δ mice showed an earlier EAE disease onset and 
compared with WT control mice when immunized with a 
suboptimal dose of MOG35-55 peptide (Fig. 5 D). In addition, 
EPCRδ/δ mice showed enhanced EAE severity compared 
with WT littermate control or heterozygous mice from the 
same cross (Fig. 5 E), indicating a functional role for PRO CR 
in disease pathogenicity. This was also reflected in increased 
levels of the proinflammatory cytokines IL-17A, IFN-γ, and 
GM-CSF in the CNS-infiltrating lymphocytes in EPCRδ/δ 
mice (Fig. 5 G). To analyze whether the observed difference 
in EAE susceptibility was caused by the effects of PRO CR 
on Th17 pathogenicity, we compared the ability of WT my-
elin-specific 2D2 Th17 cells and EPCRδ/δ 2D2 Th17 cells 
to induce disease. As Th17 cells differentiated from EPCRδ/δ 
2D2 mice yielded a higher frequency of IL-17+ T cells, we 
normalized the amount of transferred cells to the IL-17+ 
cells to be able to compare their pathogenicity per Th17 cell. 
PRO CR-deficient 2D2 Th17 cells displayed markedly en-
hanced pathogenicity, as reflected in increased clinical score 
and lethality (Fig. 5 F). Differences in number and function of 
WT vs. EPCRδ/δ 2D2 Th17 cells in the CNS could account 
for the increased pathogenicity. The total number of CNS- 
infiltrating cells (Fig. 5 H), and the number of infiltrating 2D2 
cells (Fig. 5 I) was comparable in both groups. IFN-γ pro-
duction in CNS-infiltrating T cells was low because disease 
was induced by Th17 cells. Nevertheless, IFN-γ, as well as 
IL-17 and GM-CSF, production were dramatically increased 
in CNS-infiltrating EPCRδ/δ 2D2 T cells (Fig. 5 J). Our re-
sults therefore suggest that PRO CR decreases pathogenicity 
of Th17 cells in vivo by regulating cytokines of the proin-
flammatory module, affecting pathogenicity and not neces-
sarily the differentiation of Th17 cells.
DIS CUS SION
The Th17 lineage includes a diverse spectrum of functional 
subtypes that are adapted and specialized to fulfill different 
functions. These range from being important mediators of 
host defense and homeostasis at barrier sites to acting as the 
effector cell type in several inflammatory and autoimmune 
diseases. Although several different cytokines have been iden-
tified that favor the differentiation of Th17 cells with differ-
ent functional phenotypes, the cellular receptors that mediate 
the functional transition between proinflammatory and reg-
ulatory Th17 subtypes have not been described. In this study, 
we identified PRO CR as such a receptor that acts as a nega-
tive regulator of Th17-mediated pathogenicity.
Single-cell genomic analysis of pathogenic and non-
pathogenic Th17 cells revealed the presence of two gene 
modules that influence Th17 function (Gaublomme et al., 
2015). PRO CR is preferentially expressed in nonpathogenic 
Th17 cells and covaries with the regulatory module, suggest-
ing that it could potentially act as a negative regulator of Th17 
pathogenicity. Analyzing PRO CR function, we found that 
it only has a minor dampening effect on Th17 differentia-
tion. However, PRO CR regulates several key molecules of 
the proinflammatory module in Th17 cells that determine 
their pathogenicity, including expression of IL-1R and -23R, 
both of which are critical for the generation of pathogenic 
Th17 cells (Cua et al., 2003; Sutton et al., 2006; Awasthi et al., 
2009; Chung et al., 2009). Interestingly, there appears to be 
some sort of antagonism between expression of IL-1 and -23 
receptors on one hand and PRO CR on the other hand. Con-
sistent with this observation, we detected an increase in the 
expression of PRO CR in the absence of IL-23R signaling in 
IL-23R−/− Th17 cells and loss of PRO CR signaling in the 
PRO CR mutant mice resulted in an increase in the expres-
sion of both IL-23R and -1R. This suggests that one possible 
mechanism by which IL-23 promotes Th17 pathogenicity 
might be by reducing the expression of PRO CR, which 
regulates pathogenicity by inhibiting expression of multiple 
members of the proinflammatory module. Although the mo-
lecular mechanism for this cross-regulation between PRO 
CR and IL-23R/IL-1R is still being worked out, this study 
shows that PRO CR and IL-1R/IL-23R functionally antag-
onize each other and support conversion from pathogenic to 
nonpathogenic Th17 cells or vice versa. This observation is 
further supported by independent observations in humans, 
where Th17 cells that coproduce IL-17 with IFN-γ require 
IL-1β signaling for their induction (Zielinski et al., 2012). In 
addition, the nonpathogenic Th17 cells that coproduce IL-10 
and have lower expression of IL-23R, also produce IL-1RN, 
which actively inhibits IL-1 signaling.
In healthy individuals, the majority of Th17 cells are non-
pathogenic and found at mucosal sites where they promote 
tissue repair and help maintain barrier functions (McAleer 
and Kolls, 2011). It would therefore make sense that the de-
fault Th17 differentiation program would favor a nonpatho-
genic phenotype that can then be converted into pathogenic 
Th17 cells in the presence of additional proinflammatory sig-
nals, such as IL-1β or -23. Interestingly, PRO CR expression 
is induced by RORγt, STAT3, and IRF4, three transcription 
factors that drive differentiation of Th17 cells. This suggests 
that the Th17 differentiation program includes the induction 
of surface molecules that act as intrinsic negative regulators 
(like PRO CR) to control pathogenicity of the Th17 lineage 
and to skew Th17 cells toward a nonpathogenic phenotype 
under steady-state conditions. In addition to tipping the bal-
ance to favor nonpathogenic Th17 cells under steady-state 
conditions, PRO CR might also be acting as an active brake 
during an ongoing proinflammatory Th17 response. The 
proinflammatory cytokines IL-1β and -23 actively down-reg-
ulate this brake, promoting a proinflammatory phenotype in 
Th17 cells. Although IL-1β and -23 can induce pathogenic 
Th17 cells, PRO CR engagement through its ligand aPC 
allows for a functional conversion of pathogenic into non-
pathogenic Th17 cells. The fact that the PRO CR ligand aPC 
has a known antiinflammatory function and is used clinically 
as a treatment in severe sepsis would support this hypothesis. 
o
n
 January 23, 2017
D
ow
nloaded from
 
Published September 26, 2016
2497JEM Vol. 213, No. 11
Figure 5. PRO CR ameliorates Th17 pathogenicity in vivo. (A) Frequency of CD4+ T cells expressing IL-17A and PRO CR isolated from EAE mice 21 d after 
immunization with MOG35-55 in CFA. (B) 10 d after immunization, spleen and lymph node cells were isolated and restimulated with MOG35-55 peptide in vitro 
and proliferation was determined by 3H-Thymidine incorporation 2 d later. (C) IL-17 secretion of T cells in supernatants from B was determined using ELI SA. 
(A–C) Representative plots from one of three independent experiments are depicted (5–11 mice/group). (D) WT and EPCRδ/δ mice were immunized for EAE 
with a suboptimal dose of MOG35-55 (20 µg/mouse) and observed for clinical signs of disease. Mean clinical score ± SD (left) and linear regression curves of 
the disease for each group are shown (right; the 95% confidence intervals are represented with dashed lines). (E) WT, EPCRδ/WT, and EPCRδ/δ littermates 
were immunized for EAE (100 µg MOG35-55/mouse) and observed for clinical signs of disease. Mean clinical score ± SD (left) and linear regression curves 
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An active regulatory role through aPC ligation is further sup-
ported by the fact, that protein C inhibitor is contained in the 
highly inflammatory environment of chronic active plaques 
of MS patients (Han et al., 2008). Exogenous administration 
of aPCs was shown to ameliorate EAE and affect cytokine 
production by macrophages, astrocytes, and T cells (Han et 
al., 2008). Our data suggests that aPCs may directly engage 
PRO CR on Th17 cells and limit their pathogenicity by in-
hibiting genes of the proinflammatory module in Th17 cells. 
In line with these results, we observed increased EAE severity 
in EPCRδ/δ mice. This increase in EAE severity could also 
be achieved by simply deleting PRO CR expression on en-
cephalitogenic Th17 cells, suggesting that the difference in 
disease severity observed after aPC administration must have 
been caused in part by its direct effects on encephalitogenic 
Th17 cells, supporting the idea that PRO CR acts as a nega-
tive regulator of Th17 pathogenicity in vivo.
A follow up study showed that aPC not only has a ben-
eficial effect in EAE when given at disease induction but is 
also effective when given therapeutically (Han et al., 2008). 
Our data would suggest that administration of aPC results in 
increased binding of PRO CR on Th17 cells and promotes 
a functional shift from a pathogenic toward a nonpatho-
genic phenotype in these cells, partly by inhibiting IL-1R 
and -23R signaling by controlling the receptor expression. 
PRO CR could thus potentially be targeted to therapeutically 
modulate the pathogenic phenotype of Th17 cells in auto-
immune diseases. In addition to its expression on Th17 cells, 
our preliminary data suggests that Th1 cells, when chron-
ically activated, also begin to express PRO CR and therefore 
aPC may not only affect pathogenic Th17 cells but also en-
cephalitogenic Th1 cells.
The latest generation of immunotherapies that target 
co-stimulatory pathways has shown remarkable promise for 
the treatment of pathologies caused by dysregulated immune 
responses. Anti–IL-17A and –IL-17R antibodies have been 
shown to have therapeutic efficacy in psoriasis, ankylosing 
spondylitis, and MS, but showed no benefit to or even exacer-
bated inflammatory bowel disease. The reason for this difference 
in efficacy in different autoimmune diseases has not directly 
been elucidated, but one could speculate that anti–IL-17 and 
–IL-17R antibodies may also affect nonpathogenic Th17 cells 
that decorate the lamina propria and promote gut barrier func-
tion. Based on its expression and regulatory effects on proin-
flammatory Th17 cells, PRO CR could potentially serve as an 
interesting therapeutic target that could be used to modulate 
the phenotype of pathogenic Th17 without affecting beneficial 
effects of Th17 cells that help maintain mucosal barriers.
MAT ERI ALS AND MET HODS
Mice and induction of EAE
7–10-wk-old C57BL/6 mice were purchased from The Jack-
son Laboratory or bred in our animal facility at the Harvard 
Institutes of Medicine. 2D2 (Bettelli et al., 2003), Il23R−/− 
(Awasthi et al., 2009), and EPCRδ/δ mice (F. Castellino, 
University of Notre Dame, Notre Dame, IN; Castellino et 
al., 2002) have been described previously. EPCRδ/δ mice 
are >98.7% identical to the WT controls, with most of the 
differences found in the region of genetic modification, as 
determined by SNP analysis. Mice were induced for EAE 
by subcutaneous injection with 100 µl of an emulsion con-
taining complete Freund’s adjuvant, 250 µg Mycobacterium 
tuberculosis extract H37-Ra (Difco), and 20 µg MOG35-55 
peptide (QCB BioSource International). Mice received 200 
ng pertussis toxin (List Biological Laboratories) i.p. on days 0 
and 2. For passive induction of EAE, cells were differentiated 
and adoptively transferred as described (Jäger et al., 2009). 
Mice were housed in a specific pathogen–free animal facility 
at the Harvard Institutes of Medicine. All breeding and exper-
iments were reviewed and approved by the Institutional An-
imal Care and Use Committee of Harvard Medical School.
In vitro T cell differentiation
Naive CD4+CD62L+ T cells were purified from mouse spleen 
or lymph node single-cell suspension using MACS magnetic 
beads (Miltenyi Biotec), followed by purification of naive 
T cells by flow cytometry. Cells were cultured in DMEM 
(Invitrogen) and supplemented as previously described (Lee 
et al., 2012). For Th cell differentiation, cells were activated 
with plate-bound antibody to CD3 (2 µg/ml; 145-2C11) 
and CD28 (2 µg/ml; PV-1) or anti-CD3 (2.5 µg/ml; 145-
2C11) with irradiated splenocytes as APCs in the presence 
of the following cytokines: IL-12 (10 ng/ml) was added for 
Th1, IL-4 (10 ng/ml) for Th2, and TGF-β (2.5 ng/ml), IL-6 
(25 ng/ml), IL-1β (20 ng/ml), and IL-23 (10 ng/ml) were 
added in multiple combinations for Th17 conditions. Where 
indicated, aPC (300 nM; a gift from J.H. Griffin, The Scripps 
Research Institute, La Jolla, CA) was added on day 0.
FACS and ELI SA
For intracellular cytokine staining, cells were restimulated for 
4 h with 50 ng/ml phorbol 12-myristate 13-acetate and 1 µM 
of the disease for each group are shown (right; the 95% confidence intervals are represented with dashed lines). (F–I) WT recipients were transferred with 
WT 2D2 or EPCRδ/δ x 2D2 TCR transgenic Th17 cells differentiated with TGF-β1 + IL-6 and monitored for EAE. The data represents one of three transfers 
(n = 6). (F) Mean clinical score ± SD (left) is shown, and linear regression curves of the disease for each group are depicted on the right (95% confidence 
intervals are represented with dashed lines). (G) IFN-γ, IL-17A, and GM-CSF secretion among CNS infiltrating CD4+ cells on day 16 after immunization. The 
number of total (H) and Vβ11+ 2D2 (I) CNS infiltrating cells was determined 20 d after transfer. (J) IFN-γ, IL-17A, and GM-CSF secretion among Vβ11+CD4+ 
cells was determined by flow cytometry. Representative plots of at least three independent experiments are depicted. EAE experiments were performed with 
5–11 mice/group as indicated, and plots of representative experiments of two to three repeats are depicted. **, P < 0.01; ***, P < 0.001 (Student's t test).
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ionomycin (Sigma-Aldrich) in the presence of GolgiStop 
(BD). Cells were fixed with Cytofix/Cytoperm Fixation and 
Permeabilization Solution (BD) and stained for intracellular 
cytokines. Cells were analyzed on a FAC SCalibur (BD). An-
tibodies to the following antigens were used: CD201 (EPCR; 
eBio1560; eBioscience), CD4 (RM4-5; BioLegend), IL-17A 
(TC11-18H10.1; BioLegend), IFN-γ (XMG1.2; BioLegend), 
CD62L (MEL-14; BioLegend), CD44 (IM7; BioLegend), 
IL-1R (JAMA-147; BioLegend), and GM-CSF (MP1-22E9; 
BioLegend). All flow cytometric data were analyzed using 
FlowJo Software (Tree Star). IL-17A concentration in the su-
pernatant was determined by ELI SA using standard protocols.
Quantitative RT-PCR
Total RNA was extracted using RNeasy reagents (QIA 
GEN) and reverse transcription was performed using iScript 
Reverse transcription (Bio-Rad Laboratories). Real-time 
PCR was done using validated TaqMan probe sets to mouse 
Procr (Mm00440992_m1), Il3 (Mm00439631_m1), Cxcl3 
(Mm01701838_m1), Ccl4 (Mm00443111_m1), Tbx21 (Ap-
plied Biosystems, Mm00450960_m1), Icos (Mm00497600_
m1), Csf2 (Mm01290062_m1), Il6st (Mm00439665_m1), 
Il22 (Mm00444241_m1), Il23r (Mm00519943_m1), Il1r1 
(Mm00434237_m1), and GAP DH (Mm99999915_g1).
ChIP
Lysates were generated from WT Th17 cells differenti-
ated for 4 d in the presence of TGF-β1 + IL-6 using the 
SimpleChIP Enzymatic Chromatin IP kit (Cell Signaling 
Technology) according to the manufacturer’s specifications. 
Immune precipitation was performed with 3 µg antibody 
(rabbit polyclonal anti-phospho STAT3 [#9134; Cell Sig-
naling Technology], rat monoclonal anti-Rorγt [AFK JS-9; 
14–6988-80; eBioscience], and goat polyclonal anti-IRF4 
[sc-6059; Santa Cruz Biotechnology, Inc.] or the respective 
isotype controls from the same manufacturer). To quantify 
DNA, real-time qPCR was performed using the Fast SYBR 
Green Master Mix (Applied Biosystems) with the following 
primers: promoter region of Procr (promoter 1: 5′-CAG CAC 
TCA GAA GGC AGG GTA AG-3′ and 5′-GCC AGG GCT AC 
A CAG AAA AAC CC-3′), promoter region of Procr (pro-
moter 2: 5′-GAC TAT GAC CTG TCC GAT GCT GAG-3′ 
and 5′-CGA TGA CGG CAG ATC CAG GAT TGG-3′), pro-
moter and start codon region of Procr (promoter3+ORF1: 
5′-AAG CCT GAC TCC CTC TTC CTG CAC GC-3′ and 5′-
GCC TTG ACC CAA ACT CAC CAT CGG-3′), open reading 
frame of Procr (ORF2: 5′-GTG GAG GTT GTG ATG GGA 
AGG AGG-3′ and 5′-GGC GCA CCA CAA GTC AAT GTG 
TGC-3′), and open reading frame of Procr (ORF3: 5′-AAC 
ACT GCC AAA GCC CTT TCC TGGG-3′ and 5′-GGC CCT 
 AGT TGC CTT TTC TGG CG-3′).
Procr promoter assay
The pGL4-Procr construct was generated by cloning a 1,040-
bp fragment of the murine Procr promoter (-1040 – +1 bp 
from TSS) into the pGL4.10 vector (Promega) using KpnI/
BglII sites, and verified by sequencing. HEK 293T cells were 
transiently cotransfected with the pGL4-Procr construct, an 
empty Renilla luciferase reporter vector, and the indicated 
transcription factor expression vectors using Fugene HD 
(Roche). Luciferase activity was analyzed 48 h after transfec-
tion using a dual luciferase assay kit (Promega).
Retroviral transduction
For retroviral production, HEK 293T cells were seeded at 
the density of 1.5 × 106 cells in 10-cm dishes 24 h before 
transduction. 4.5 µg pCMV5 containing the Procr mRNA 
along with 1 µg pcl and 2 µg gag/pol viral envelope con-
structs were transfected using Fugene HD (Promega). Virus 
containing supernatant was collected 48 h after transfection. 
For transduction, naive CD4+ T cells were activated with 
plate-bound anti-CD3 and anti-CD28 and spin-infected at 
2,000 rpm for 45 min in the presence of polybrene (Sigma- 
Aldrich; final 8 ng/ml).
Single-cell RNA-Seq analysis
The experimental protocol for the single-cell RNA-seq data 
acquisition, as well as alignment, normalization, and filtering 
of the data are provided in the original study (Gaublomme et 
al., 2015). In total, 755 Th17 cells, either harvested in vivo or 
differentiated in vitro, were profiled transcriptionally based on 
mRNA SMA RT-Seq libraries derived from single cells using 
microfluidic chips (Fluidigm C1). At least two independent bi-
ological replicates for each condition were analyzed. RNA-seq 
reads were aligned to the National Center for Biotechnology 
Information Build 37 (UCSC mm9) of the mouse genome 
using TopHat (Trapnell et al., 2009). The resulting alignments 
were processed by Cufflinks to evaluate the abundance (using 
FPKM) of transcripts from RefSeq (Pruitt et al., 2007). We 
used log transform and quantile normalization to further nor-
malize the expression values (fragments per kilobase of exon 
per million; FPKM) within each batch of samples (i.e., all 
single cells in a given run). To account for low (or zero) ex-
pression values, we added a value of 1 before log transform. We 
filtered the set of analyzed cells by a set of quality metrics (such 
as sequencing depth), and added an additional normalization 
step specifically controlling for these quantitative confounding 
factors, as well as batch effects. Our analysis is based on ∼7,000 
appreciably expressed genes (FPKM > 10 in at least 20% of 
cells in each sample) for in vitro experiments and ∼4,000 for 
in vivo ones. We also developed a strategy to account for ex-
pressed transcripts that are not detected (false negatives) due 
to the limitations of single-cell RNA-seq (Deng et al., 2014; 
Shalek et al., 2014). Our analysis (e.g., computing signature 
scores) down-weighted the contribution of less reliably mea-
sured transcripts. To compute the pathogenic signature score 
(Fig. 4 A), we first standardized the expression matrix for each 
gene, then, for each cell, we define the score as the weighted 
mean of the normalized values of the propathogenic genes in 
the signature minus the nonpathogenic genes.
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